Jefferies analyst Raj Denhoy lifted estimates and his price target on Buy-rated Hologic (NASDAQ: HOLX) to $26.00 (from $24.00) following solid Q2 results.

Denhoy commented, "HOLX put up a F2Q beat on strength in Tomo and APTIMA along with significant cost cutting under new CEO. Full-year guidance was raised but with expectations for higher investments in F2H. The key growth areas of the business are finally eclipsing the weaker parts and cost reduction is evident. Although 90 days doesn’t make a trend, F2Q was certainly a good start."

The firm raised FY 2014 EPS from $1.35 to $1.39 and FY 2015 EPS from $1.50 to $1.51.

For an analyst ratings summary and ratings history on Hologic click here. For more ratings news on Hologic click here.

Shares of Hologic closed at $20.99 yesterday.